Synairgen plc

OTCPK:SYGG.F Stock Report

Market Cap: US$6.5m

Synairgen Management

Management criteria checks 4/4

Synairgen's CEO is Richard Marsden, appointed in Sep 2009, has a tenure of 15.25 years. total yearly compensation is £328.00K, comprised of 94.5% salary and 5.5% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth $31.89K. The average tenure of the management team and the board of directors is 3.9 years and 8.8 years respectively.

Key information

Richard Marsden

Chief executive officer

UK£328.0k

Total compensation

CEO salary percentage94.5%
CEO tenure15.3yrs
CEO ownership0.5%
Management average tenure3.9yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Richard Marsden's remuneration changed compared to Synairgen's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£7m

Mar 31 2024n/an/a

-UK£8m

Dec 31 2023UK£328kUK£310k

-UK£8m

Sep 30 2023n/an/a

-UK£9m

Jun 30 2023n/an/a

-UK£10m

Mar 31 2023n/an/a

-UK£14m

Dec 31 2022UK£328kUK£310k

-UK£18m

Sep 30 2022n/an/a

-UK£23m

Jun 30 2022n/an/a

-UK£28m

Mar 31 2022n/an/a

-UK£38m

Dec 31 2021UK£1mUK£256k

-UK£49m

Sep 30 2021n/an/a

-UK£46m

Jun 30 2021n/an/a

-UK£43m

Mar 31 2021n/an/a

-UK£28m

Dec 31 2020UK£415kUK£194k

-UK£14m

Sep 30 2020n/an/a

-UK£10m

Jun 30 2020n/an/a

-UK£6m

Mar 31 2020n/an/a

-UK£5m

Dec 31 2019UK£289kUK£190k

-UK£4m

Sep 30 2019n/an/a

-UK£4m

Jun 30 2019n/an/a

-UK£4m

Mar 31 2019n/an/a

-UK£3m

Dec 31 2018UK£205kUK£186k

-UK£3m

Sep 30 2018n/an/a

-UK£898k

Jun 30 2018n/an/a

UK£2m

Mar 31 2018n/an/a

UK£2m

Dec 31 2017UK£336kUK£182k

UK£2m

Compensation vs Market: Richard's total compensation ($USD411.17K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Marsden (57 yo)

15.3yrs

Tenure

UK£328,000

Compensation

Mr. Richard Marsden has been Chief Executive Officer of Synairgen Research Ltd since September 2009. Mr. Marsden has been Managing Director and Executive Director at Synairgen since June 2004 has been its...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Marsden
CEO, MD & Executive Director15.3yrsUK£328.00k0.49%
$ 31.9k
Stephen Holgate
Co-Founderno dataUK£40.00k0.45%
$ 29.2k
Joseph Colliver
CFO & Executive Director1.1yrsUK£197.41kno data
Phillip Monk
Chairman of Scientific Advisory Board15.3yrsUK£241.00k0.21%
$ 13.6k
Donna Davies
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ratko Djukanovic
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Gareth Walters
Chief Regulatory Officer3.2yrsno datano data
Jody Brookes
Senior VP & Head of Clinical Operations13yrsno datano data
Richard Francis
Senior VP and Head of CMC & Quality3.3yrsno datano data
Victoria Tear
Head of Laboratory5.7yrsno datano data
Marcin Mankowski
Chief Medical Officer1.2yrsno datano data
Simon Holden
Company Secretary3.9yrsno datano data

3.9yrs

Average Tenure

56yo

Average Age

Experienced Management: SYGG.F's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Marsden
CEO, MD & Executive Director20.5yrsUK£328.00k0.49%
$ 31.9k
Stephen Holgate
Co-Founder21.5yrsUK£40.00k0.45%
$ 29.2k
Joseph Colliver
CFO & Executive Director1.1yrsUK£197.41kno data
Phillip Monk
Chairman of Scientific Advisory Board15.3yrsUK£241.00k0.21%
$ 13.6k
Donna Davies
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ratko Djukanovic
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Mark Parry-Billings
Chairmanless than a yearno datano data
David Campbell
Non-Executive Director & Member of Scientific Advisory Board18.7yrsUK£40.00k0.16%
$ 10.6k
Felicity Gabbay
Member of Scientific Advisory Board & Independent Non-Executive Director2.3yrsUK£45.00kno data
Amanda Radford
Independent Non-Executive Director2yrsUK£45.00kno data

8.8yrs

Average Tenure

57yo

Average Age

Experienced Board: SYGG.F's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:50
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synairgen plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCavendish
Mark BrewerCavendish
Paul CuddonNumis Securities Ltd.